Fulvestrant (F) plus sorafenib (S) as salvage therapy for hormone receptor positive (HR+) metastatic breast cancer (MBC) failing prior aromatase inhibitor (AI) treatment.
Kristine H. Lethert
No relevant relationships to disclose
Deirdre J. Nauman
No relevant relationships to disclose
Yolanda Prado
No relevant relationships to disclose
Mark Seligman
No relevant relationships to disclose
Kasra Karamlou
No relevant relationships to disclose
Frederick S. Ey
No relevant relationships to disclose
Stephen Y. Chui
No relevant relationships to disclose